Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

British Society of Gastroenterology

Annual Report and Financial Statements

31 December 2025

Charity Registration Number 1149074

Company Limited by Guarantee

Registration Number 08124892 (England & Wales)

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

British Society of Gastroenterology 1
Introduction ... 3
Reference and administrative details of the Society, its Trustees and advisers ... 5
Report from the BSG Chair of the Trustees ... 7
Our Purpose ... 8
Charitable Objects ... 8
Our Activities and Achievements ... 10
Membership ... 10
Project 90 ... 10
Recognising our Members ... 11
BSG Events ... 12
Education ... 14
Clinical Services and Standards ... 15
Research ... 16
Training ... 17
International Engagement ... 17
The 2025 European Specialty Examination in Gastroenterology and Hepatology ... 19
Climate Change and Sustainability ... 19
Our Journals ... 20
Future activities – 2026 ... 21
Our Structure and Governance ... 22
Our Structure ... 22
Operational Staff ... 25
Fundraising ... 25
Organisational Governance Achievements ... 25
Equality, Diversity and Inclusion ... 26
Risk Management ... 27
Financial report for the year ... 28

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Introduction

The British Society of Gastroenterology (the 'Society' or BSG) had a record year in 2025 with record membership levels and the highest ever conference attendance for a BSG LIVE held in Glasgow. The BSG continues to modernise and deliver an outstanding job in delivering high quality journals, practice changing guidelines, impactful meetings and a wide and diverse range of events and support for our members.

2025 has seen our specialty continue to operate within a climate of sustained pressure. Services are managing rising demand, constrained resources and workforce gaps, while clinicians balance complex clinical workloads with responsibilities for training, mentoring, research and high-quality patient care. The need to protect time for education and professional development, without compromising service delivery, has never been more acute.

In response, the BSG has focused on providing practical, targeted support. This has included extending engagement beyond consultant gastroenterologists to the wider multidisciplinary workforce upon whom the specialty depends - clinical endoscopists, specialist and general nurses, GPs and allied health professionals. By recognising the interdependence of these roles, the Society has worked to strengthen the whole clinical team rather than a single professional group.

In 2025, the BSG commenced a comprehensive governance review to ensure the organisation remains modern and representative of its growing and diverse membership which will be completed in 2026. The review examined committee structures, decision-making processes, leadership pathways and accountability, with the aim of strengthening member engagement and future-proofing the Society. A central principle was to enhance democratic participation while maintaining stability, continuity and strategic oversight.

One of the most significant outcomes of the review was the introduction of a new process for selecting the President-Elect. Launched at the end of 2025, the revised approach moved to a member-chosen President-Elect, elected directly by the membership rather than appointed through the previous internal mechanism. This (initial pilot) change reflects a clear commitment to increased inclusivity and member voice at the highest level of leadership.

The Society continued to grow in scale and influence, reaching record membership levels and expanding our journal portfolio, including the launch of a new title, 'Gut Science'. We delivered a substantial programme of activity designed to strengthen standards of care while investing directly in the professional and personal development of our members.

In 2025, the BSG launched a new initiative to support trainees undertaking the ESEGH examination by providing a financial contribution towards the associated costs. Covering the 2021 to 2024 period, we were able to award candidates £300 per exam, amounting to £89,000. This resoundingly popular offer has led to the BSG planning to support members further with the exam costs.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

A defining theme of the year was a sustained investment in events, education and career progression. Project 90, a project providing enhanced membership benefits in the run-up to BSG 90th birthday, launched with Travelling Fellowships, leadership training and events around the UK and will continue to develop its legacy over the next two years. We also introduced leadership and coaching training in recognition of the crucial need to support our workforce in developing the next generation, especially in the face of staffing shortfalls across the specialty. We delivered BSG LIVE'25 with record-breaking attendance, opened abstract submissions early for 2026, alongside running 17 webinars, multiple section speciality meetings, trainee-focused events, undergraduate support. We introduced support for IUS training, hosted a UEG examination event and led a Pathology EQA event.

BSG President, Professor Colin Rees

BSG CEO, Mrs Sarah Linnington

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Reference and administrative details of the Society, its Trustees and advisers

Trustees	Dr S Al-Shamma (appointed 26 June 2025) Ms M Azdejkovic Dr U Basavaraju (resigned 26 June 2025) Prof P Bhandari Mr T Budd Dr M Cowan Ms J Flitcroft (resigned 31 October 2025) Dr H Gordon Dr C Hollywood (resigned 26 June 2025) Mr T Jones Mrs R Lloyd (resigned 31 December 2025) Ms S Marshall (appointed 26 June 2025) Mr P McCauley Prof D S McPherson (appointed 26 June 2025) Dr A J Morris Prof C Rees Prof H Steed (resigned 26 June 2025) Ms V Valentine (appointed 2 December 2025) Mrs M Watters (appointed 2 December 2025)
Chief Executive	Mrs S Linnington
Registered/Principal Office	3 St Andrews Place Regent's Park London NW1 4LB
Telephone	020 7935 3150
E-mail	president@bsg.org.uk
website	www.bsg.org.uk
Charity Registration Number	1149074
Company Registration Number	08124892 (England and Wales)

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Auditor	Moore Kingston Smith LLP 6th Floor 9 Appold Street London EC2A 2AP
Solicitors	Druces LLP Salisbury House London Wall London EC2M 5PS
Bankers	National Westminster Bank Plc PO Box 2021 10 Marylebone High Street London W1A 2AS
Investment Managers	CCLA Senator House 85 Queen Victoria Street London EC4V 4ET

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Report from the BSG Chair of the Trustees

I am pleased to present the Annual Report on behalf of the Trustees alongside the financial statements of the BSG and its subsidiary company BSG Limited (together the 'Group' or 'consolidated') for the year ended 31 December 2025.

This report has been prepared in accordance with Part 8 of the Charities Act 2011 and constitutes a directors' report for the purposes of company legislation.

The financial statements have been prepared in accordance with the accounting policies set out on pages 39 to 42 of the attached financial statements and comply with the charitable company's Memorandum and Articles of Association, applicable laws and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

Professor Colin Rees
BSG President & Chair of Board of Trustees June 2024 to June 2026

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Our Purpose

The purpose of the Society is the promotion of good health through high standards of patient care, clinical service provision, research and education in gastrointestinal and liver disease in the United Kingdom and internationally.

Charitable Objects

The BSG primarily pursues its charitable objects by supporting members in their professional capacities. This purpose is achieved through a series of workstreams related to the charitable objects of research, education and training, clinical standards and membership support.

Clinical Standards

To promote high-quality patient care and the definition of best practice by:

- Developing and disseminating guidelines of best clinical practice in gastroenterology and hepatology.
- Developing outcome measures which can be used to assess quality standards.
- Developing and using digital technologies for the benefit of clinical practice.
- Developing and encouraging methods of peer review and audit of clinical practice.
- Providing technical guidance on specialist areas of practice.

Research

To promote the discovery and dissemination of scientific knowledge by:

- Supporting the membership to participate in clinical and basic research.
- Encouraging clinicians to undertake research through training, networking and guidance.
- Defining research priorities for investigation into digestive diseases in the United Kingdom working with other national stakeholders.
- Holding regular presentations of research findings.

Education and Training

To promote this object by:

- Contributing to the development of national and international programmes of training and learning.
- Promoting high-quality educational opportunities by the endorsement of symposia, meetings and other digital educational materials for dissemination through the Society's website and other digital platforms.
- Journal ownership and publication: working as partners with BMJ Publishing Group Ltd to promote the Society's co-owned journals encouraging the publication of high quality clinical and translational science.

Membership Benefit and Workforce

To provide support to the professional community by connecting members through active networking, the dissemination of information and supporting their lifelong professional development and learning by:

- Working to identify, understand and respond to issues which affect workload and the well-being of the workforce.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

- Defining the numbers of gastroenterologists required to provide high-quality care and reporting accurate annual workforce numbers.
- Developing the next generation of leaders in our field.
- Promoting equality and diversity in our workforce and leadership.
- Providing informed professional advice to other professional groups, stakeholders and healthcare partners in the charity sector and directly to the United Kingdom Government and devolved administrations where possible.
- Engagement of the international community of gastroenterologists and hepatologists in collaboration which supports the delivery of the Society's charitable objects.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Our Activities and Achievements

Membership

In December 2025, our total number of members across different categories were as follows:

	2024 No.	**2025** No.
Honorary	95	95
Full	1585	1605
International	124	121
Trainee	784	869
Senior	84	78
Associate	304	332
Nurse	792	819
Taster	647	694
Undergraduate	78	49
	4,493	**4,662**

Membership growth slowed slightly from 5.5% the previous year, to 3.8% with most of that growth occurring at Trainee level. Growth opportunities have been identified in Nurse, Associate and Undergraduate memberships and campaigns are being planned for 2026 to build on strong work to develop BSG membership across the specialty and MDTs.

Project 90

The BSG will celebrate its 90th birthday in 2027 and plans to celebrate the profession and the membership by providing enhanced membership benefits in the run-up to this birthday with an overarching aim of allowing members to discover or re-discover their passion for the profession and specialty.

In 2025, with Dr Beverly Oates as overall Clinical Lead, and managed by BSG's Head of Projects, Nicola Husbands, we established five workstreams, designed for multi-disciplinary access:

- Nurse education – Dr Phedra Dodds
- Travelling fellowships – Dr Mo Thoufeeq
- Leadership and Management – Dr Monica Bose
- Regional meetings – Dr Umesh Basavaraju
- Career support – Dr John McGoran

Whilst 2024 gave the projects team the opportunity to scope and plan each workstream, 2025 saw the formal launch and flourishing of many initiatives.

Leadership and Management Workstream

The BSG launched a flagship 'Improvement Leadership' programme in association with AQuA, specialists in leadership and quality improvement programmes. The aim was to equip participants with the skills, networks and confidence to lead meaningful service improvements across the specialty. 2025 saw the launch of the inaugural programme and the first two residential blocks.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Career Support Workstream

This workstream introduced two new initiatives to support members throughout their careers. We included a new Group Coaching Programme, designed to support member development and professional growth; and developed a one-off Introduction to Coaching Skills workshop which took place in November. The first and second cohorts of Group Coaching participants "Pathways to Greater Career Satisfaction" and "Pathways to a New Role" were recruited and onboarded.

Travelling Fellowships Workstream

Project 90 introduced a travelling fellowship programme for members with the aim of providing inspiration, insight and develop new relationships between different national and international gastroenterology and hepatology teams. During 2025, we developed application assets, recruited host centres and piloted the scheme amongst 4 travelling fellows. This allowed us to iterate the programme for the first substantive cohort launching in 2026.

Nurse Education Workstream

The Nurse Education arm strives to empower and enhance education and training for nurses and healthcare staff in diverse gastroenterology settings, including wards, outpatient clinics, theatres, and critical care.

We developed a wireframe journey of learning which went out to peer review. The process of developing content around this wireframe was started, and discussions were initiated with NHS Learning Hub and other commercial LMS providers.

Project 90 – Regional meetings Workstream

Our Regional Meetings Workstream is dedicated to expanding the reach of gastroenterology by actively engaging with all four regions across the UK. Our goal is to strengthen the interconnectivity between these regions, ensuring a more unified and collaborative approach to delivering high-quality gastroenterological care and education. 2025 saw the first regional meeting take place in Cardiff with the joint BSG:WAGE conference in October, including a "Meet the BSG" reception.

Recognising our Members

The BSG is keen to encourage and recognise members across all stages of their career, and in all specialties. The BSG runs a significant Awards programme, including:

- The President's Medal is bestowed by the BSG President. In 2025, Dr Beverley Oates and Dr Mark Donnelly received the medals for their outstanding contribution to EndoVillage at BSG LIVE'25; and to the BSG Membership Secretary Ms Janet Bassett for services to members.
- The Arthur Hurst Lecture is given by a leader in gastroenterology and invited by the BSG President. This year, the lecture was given by Professor Mark Hull, Professor in neuro-gastroenterology and consultant gastroenterologist, University College Hospital. The lecture was entitled 'Participant Observer'.
- The Sir Francis Avery Jones Award encourages research by gastroenterologists working in the UK and the Republic of Ireland. This year's winner was Dr Chris Lamb, Clinical Senior Lecturer and Honorary Consultant in Gastroenterology, Newcastle Hospitals. 'Developing a career in academic gastroenterology: Collaborate, Assimilate, Innovate, Communicate, Educate & Celebrate'.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

- The Hopkins Prize for Endoscopy recognises a technical innovation in the field of endoscopy, a new method using existing endoscopic equipment, or contribution to endoscopy research. In 2025, this was not awarded.

- The Dame Parveen Kumar Award for Education and Training was developed to recognise the excellence of trainers in gastroenterology and hepatology. The recipient in 2025 was Dr Vinay Singal, consultant gastroenterologist and interventional endoscopist, University College Hospital.

- We were pleased to present the Ian Forgacs Award at BSG LIVE'25 to Andrew Chan for "The Gut Microbiome in colorectal cancer: where are we now?", recognising work that not only advances clinical understanding but also supports more sustainable approaches to prevention, diagnosis and long-term management within gastroenterology.

BSG Events

BSG LIVE

Our Annual Meeting, BSG LIVE'25, took place in June 2025 in Glasgow, run by the conference organisers, TFI Lodestar with support from the BSG Office. The event attracted over 2,800 national and international attendees, the highest turn out in the history of the BSG Annual Meeting. We increased the streams from 6 to 7 to allow for more varied educational content and recorded all of these sessions to allow delegates to catch up on sessions in their own time. The BSG supported attendance from trainees, nurses and undergraduates through bursaries and Awards.

EndoVillage was extended to include more stations, covering a more diverse range of interests and focusing on relevance across the MDT. A deliberate effort was made to increase the amount of training available to nurses and to help delegates to select stations that were most directly beneficial and appropriate for their level of career and interests.

Trainee Events

It was another fantastic year for the trainee section. BSG LIVE'25 was incredibly successful and saw the rebrand of the undergraduate section as 'Gastroenterologists of the Future' with its best turnout so far. Plans for trainees at BSG LIVE'26 were set with some excellent sessions lined up to support the general gastro registrar with commonly encountered scenarios on-call and in clinic.

Other events in the trainee calendar went well, with positive feedback for the sold-out Taster Weekend, Taster Endoscopy, Intestinal Ultrasound, Management and Leadership course as well as the Virtual Education Weekend and the joint BSG/UEG ESEGH revision course.

The trainee podcast flourished and will transition in 2026 to support trainees undertaking the ESEGH with a revision series. Work was carried out on the BSG website to highlight key resources for trainees as well as to group together BSG-endorsed fellowships for those considering an OOP.

- We ran the 10th annual National Introduction to Gastroenterology Day, hosted at the RCP Spine Building in Liverpool, with 55 attendees.

- For the first time, we ran a Trainees Intestinal Ultrasound Taster Course in May 2025 at the University College London Hospital Education Centre, which attracted 21 delegates. The course provided senior gastroenterology trainees with an introduction to intestinal ultrasound as most trainees have limited exposure to intestinal ultrasound. Following excellent feedback, we plan to run the course again in 2026.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

- We delivered our annual Taster Course tailored for those at foundation or IMT level, which provided delegates with an insight into the huge diversity and exciting opportunities the specialty provides. We delivered several half-day hands-on Taster Endoscopy courses in Newcastle and London to inspire more aspiring endoscopists. The courses had 197 delegates in total in attendance.
- We partnered with UEG to run an Exam Masterclass for Trainees, designed to support UK and international Gastroenterology trainees preparing for the European Specialty Examination in Gastroenterology and Hepatology (ESEGH), for which 136 delegates attended.
- In 2026, we introduce the new Alistair McIntyre Prize for Improving Gastroenterology Training, with more information to come at its launch at BSG LIVE'26 where we will be joined again by members of the late Dr McIntyre's family. Alongside this, our successful events calendar continues, and we hope to introduce some new ventures for the early gastroenterology registrar to support decisions around career pathway and planning.

Other In-Person Events

- The annual IBD Investigators Day, organised by the IBD CRG, was held in January 2025 in Newcastle, attracting 95 delegates.
- In September and November, we held our Improvement Leadership Programme. As part of Project 90, this flagship programme was launched in association with AQuA, specialists in leadership and quality improvement programmes. The aim was to equip participants with the skills, networks, and confidence to lead meaningful service improvements across the specialty. The third and fourth blocks are set to run in 2026.
- In the lead up to our conference, we also offered Speaking and Chairing workshops to support 18 members of faculty with these important skills.
- We collaborated with the Clinical Endoscopists to run a hybrid conference in November with around 100 delegates as an initiative to widen the appeal of the BSG to nurse and associate members.

Webinars

- We collaborated with the Frontline Gastroenterology journal to run three webinars discussing published review articles, as well as how best to manage the increasing global burden of obesity, and care bundles for decompensated cirrhosis. The webinars had a total of 468 attendees.
- Endoscopy Question Time is a new initiative from the BSG Endoscopy Committee for insightful discussions, expert opinions, and the latest ideas in endoscopic procedures. We ran three virtual events attended by nearly 400 delegates in which attendees could submit questions in advance that they wanted experts to answer and discuss. This is set to continue into 2026 and expand to other sections such as IBD and Liver.
- We also delivered a series of webinars around Personal and Professional development, with topics including mentoring, how to handle patient safety and serious incidents, and well as making alternative career pathways work, run by the Supporting Women in Gastroenterology (SWiG) section.
- Our Vimeo platform with webinars and masterclasses received over 5700 views from over 1600 people in 2025, amounting to over 830 hours of total watch time.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Podcasts

We introduced a new podcast called “From Top to Bottom’ which launched in July 2025. Between July and December 2025, we released 10 episodes which had already achieved 1200 listens on Spotify and other streaming platforms by the end of 2025. The intention is to continue releasing regular Top to Bottom podcasts alongside the Trainee podcasts.

Education

Web Education

The BSG Web Education team published 16 videos and 7 articles covering a variety of topics. In 2025, we had a total of 41,386 views, and the web education pages were viewed by 17,626 people.

Travel Bursaries to attend BSG LIVE’25

The Education Committee was pleased to offer 67 travel bursaries, including 28 for trainees, 19 for nurses and 20 for undergraduates who otherwise would have struggled to attend the BSG Annual Meeting Conference.

BSG LIVE’25 Conference

The Education Committee was delighted to have its own first session at the BSG Annual Meeting 2025. It included a session on Mentoring, and Education for the GI Trainee in 2025.

BSG Endorsed Events

We processed, and approved, 14 applications for BSG endorsed events in 2025.

BSG Education Committee Strategy 2025-2028

The Committee produced its strategy for 2025-2028, which was approved by the BSG Executive at their meeting in December 2025. This will be published in 2026.

Royal College of Physicians (RCP) Medicine Podcast Series

Two members of the BSG web education team also assisted the RCP as interviewers for the RCP Medicine podcast series.

BSG Mentoring Programme

This initiative continues to grow steadily in all sections of the membership. offering a main programme to all members, and a focused programme to IMT members who are applying to be a GI Registrar. The IMT to GI programme had its first successes in April 2025 with most mentees achieving a GI training number with excellent feedback, and it is supporting seven more mentees in the current round of applications. We focused on advertising both programmes at events and encouraged members through a webinar to participate as mentors or mentees, and we have had a positive response to these promotions. 25 mentees and 5 mentors joined the programmes in 2025.

In 2026, we will be focusing on encouraging trainees and nurses to make use of the mentoring programme by engaging with the relevant sections to identify any barriers, and ensuring that the programme offers relevant support.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Clinical Services

Committee Strategy

The committee published its new strategy for 2025-2028. The committee shortened its name from Clinical Services and Standards Committee (CSSC) to Clinical Services committee (CS) for easier understanding of the committee's work and recall. With this change the committee also renamed their annual award to the Clinical Services Excellence Award.

Key Publications

Several high-profile guidelines/guidances were published including:

- BSG Guidelines on colorectal surveillance in inflammatory bowel disease (IBD)
- BSG Guidelines on inflammatory bowel disease in adults
- BSG Guidelines for the Management of Autoimmune Hepatitis (AIH)
- BSG Guidelines on transition and management of childhood liver diseases in adulthood
- BSG Scope of Practice of Clinical Endoscopist guidance
- BSG Guidance/Clarification of the place of UGIE in the investigation of IDA
- BSG Guidance on venesection treatment for haemochromatosis
- Decompensated cirrhosis: an update of the BSG/BASL admission care bundle
- BSG/ACPGBI Guidance on the management of colorectal polyps in patients with limited life expectancy
- BSG and Association of Upper Gastrointestinal Surgery of Great Britain and Ireland and Royal College of Pathologists Delphi consensus guidance on biopsy sampling during upper gastrointestinal endoscopy in adult patients

Following NICE's decision to end its formal accreditation process, our guidelines process underwent a strategic review. The Clinical Services committee (CS) remains committed to maintaining robust methodology standards, supported by the future recruitment of a dedicated guideline training lead to include a full review of the guideline process incorporating in-house methodologist, guideline author training, librarian support and the formation of a guideline advisory/sub-committee group.

Workforce

The anticipated Annual Workforce Report has been completed and published and provides crucial insights into gastroenterology workforce needs and challenges. The Job Planning Guidance is due to be published in 2026. A new workforce lead has been recruited to post, Dr Louise Scovell.

Quality Improvement (QI)

Several initiatives are being revitalised through a comprehensive strategic review, with plans to establish QI fellowships. Development of a service hub for clinical resources is progressing, while strengthened regional representation networks enhance engagement and implementation of BSG initiatives across regions.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

National Voice

Clinical Services actively contributes to national healthcare initiatives, including GIRFT (Getting It Right First Time) and the NHS 10 year plan. Work is ongoing to update the BSG job planning guidance document, reflecting evolving service needs and workforce patterns. Many parts of BSG engage regularly with NHSE and other stakeholders in England and the other devolved nations.

Research

In 2025, the BSG Research Committee continued to champion the integration of research and clinical care across gastroenterology and hepatology, despite unprecedented pressures within the NHS. Ongoing clinical backlogs, financial constraints, industrial action and reduced external funding have constrained research capacity, with many clinicians experiencing erosion of protected research time. The reorganisation of the NIHR into Research Delivery Networks has further challenged local delivery infrastructure. In this context, the Committee focused on reinvigorating an overstretched workforce and restoring research to the heart of BSG activity.

Research Output

Research output was strong over 2025. Over 15,000 patients have been recruited into UK-led endoscopy trials in the past five years, and hepatology continues to deliver a £15 million NIHR portfolio of landmark randomised studies shaping global practice. The Committee is supporting delivery of the NIHR Gastroenterology and Hepatology portfolio and refreshing the BSG Research Strategy, with updated priorities to be presented in early 2026. A new multidisciplinary working group was established to widen trainee engagement and make research involvement more inclusive and accessible.

Stakeholder Engagement

Stakeholder engagement has expanded significantly. Three James Lind Alliance Priority Setting Partnerships (IBS, Pancreatitis, Diverticular Disease) are now progressing delivery of their top 10 priorities. The Endoscopy PSP is nearing completion, and the IBD PSP will launch in 2026 in partnership with St Mark's Hospital and Crohn's & Colitis UK. Collaboration with charities including Guts UK and Crohn's & Colitis UK remains central, with BSG members contributing to research strategy development and funding panels. The Clinical Research Groups (CRGs) revitalised web platforms, launched active study repositories and delivered research-focused symposia at BSG LIVE'25. The Nurses Research Network continued to grow, strengthening multidisciplinary engagement across gastroenterology and hepatology.

BSG Research Scholars Programme

The BSG Research Scholars Programme, launched in 2022, now supports six scholars across endoscopy, hepatology, IBD, pancreaticobiliary disease and digital health, providing protected time and mentorship to develop high-quality studies. The BSG Supported Research Database and Statistical Support initiative, delivered with BiCOPS using REDCap, continues to underpin trainee-led multi-centre studies, with alternative partnerships under review to improve efficiency. Travel bursaries, including the EASL scheme, and prestigious awards such as the Francis Avery Jones Award continue to recognise and enable excellence among emerging and established researchers.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Trainee Research Networks

Trainee Research Networks are leading national collaborative projects, supported by a new web portal and strengthened links across the home nations. A particular highlight of 2025 was the successful BSG Introduction to Research Day for Trainees and Nurses, held in York in November. Designed collaboratively by trainees and nurses, the event provided practical training in research design, grant writing and integrating research alongside clinical roles, and was very well received. Despite systemic challenges, 2025 was a year of consolidation, renewal and strategic progress, positioning BSG research for sustainable growth in 2026 and beyond.

Training

The BSG Training Committee remained focused on supporting our current trainees and trainers to experience and deliver high quality training. We hosted our flagship event, the National Introduction to Gastroenterology Day, and we will host our first New Consultants Day later in 2026. We also continued to support both the Barbers' Company Award for Gastroenterology Trainees and the BSG Dame Parveen Kumar Award for Education and Training.

We worked with the Trainee section to produce a quality standards document with a goal to publish in the first half of 2026. In addition, we completed a document requested by NHSE exploring how the current curriculum could be developed further with the goal of supporting all those involved to receive and deliver high quality training.

BSG Training Committee Strategy 2025-2028

The Committee produced its strategy for 2025-2028, which was approved by the BSG Executive at their meeting in December 2025. This will be published in 2026.

International

Endorsed International Events Policy

The International Endorsed Events Policy was finalised and approved in executive meeting in December 2025. We have created a dedicated section within the BSG website to highlight international endorsed events policy from partner societies across global regions. Up to four events per region per quarter can be endorsed, ensuring appropriate geographic representation (India and China, Americas and Caribbean, MENA, Sub-Saharan Africa, Australia, and Europe). This initiative aims to increase BSG visibility, promote reciprocal engagement, and strengthen academic exchange. Read more here: https://www.bsg.org.uk/event-endorsement-guidance

UEG–BSG ESEGH Exam Masterclass for Trainees

Through a UEG Activity Grant secured in 2025, the Committee established a collaboration with the Malta Gastroenterology Association. The one day ESEGH focused Masterclass, held in Manchester on 4 December 2025, was designed in alignment with European Section standards and included psychological preparation, structured revision strategies, and comprehensive coverage of examination domains including endoscopic imaging and radiology interpretation. Attendance reached full capacity, reflecting strong demand. Feedback from attendees was exceptional. This model is intended to be developed as an annual educational initiative.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Memorandums of Understanding (MoUs) and International Partnerships

Significant progress was made in formalising and consolidating international collaborations:

Indian Society of Gastroenterology (ISG): Agreement was reached on key terms of collaboration, focusing on shared expertise in endoscopy, IBD, hepatology, guideline development, and curriculum design. Reciprocal conference participation has been agreed. Formal signing was held at the ISG Annual Conference in December 2025, with further celebration planned at BSG LIVE'26 in Liverpool.

Chinese Society of Gastroenterology (CSG): Following renewed high-level engagement in 2024, the MoU with CSG was formally signed during BSG LIVE'25. A successful hybrid symposium for Chinese delegates was delivered with strong in-person and online attendance. The BSG President and Vice President visited and spoke at a CSG meeting in autumn 2025. Agreed collaborative actions include reciprocal conference representation, joint scientific sessions and research collaboration development.

Bangladesh Gastroenterology Society: Ongoing collaboration has continued despite prior pandemic-related interruption. Educational webinars, in-person "train the trainer" programmes, observerships in the UK, and equipment support have been delivered. The National Gastroliver Institute Endoscopy Training Centre has progressed as a regional hub for skills development. The BSG has pledged £30,000 to support endoscopy reporting software implementation. A UK delegation visit during the BSG WAGE Autumn Meeting in October 2025 further strengthened bilateral engagement.

International Grants Programme

The International Grants programme continues to demonstrate tangible impact in education, service development, and research capacity building. The 2023–24 cohort saw five projects completed during 2025, with two entering final reporting stages. These included initiatives in endoscopy training (India, Zambia), hepatology and viral hepatitis policy development (Malawi), colorectal cancer screening (MENA), and IBD research collaborations.

In May 2025, five new projects were awarded (2025–26 cycle), spanning Pakistan, Nigeria, Rwanda, Ethiopia, and Zambia. One Rwanda-based mentorship project has already been completed, with the remaining four projects now underway. Themes include endoscopy training, endoscopy nursing education in low-resource settings, IBD educational legacy development, and consolidation of sustainable colonoscopy training programmes. The programme continues to illustrate how targeted funding of up to £10,000 per project can deliver measurable system-level benefits.

BSG International Symposium – BSG LIVE'25

The International Symposium at BSG LIVE'25 featured invited faculty from the Indian Society of Gastroenterology and senior European representation. This strengthened strategic alignment ahead of formal MoU signing with ISG in December 2025. Plans are underway for a joint BSG UEG session at BSG LIVE'26 aiming for a strong European partnership.

International Membership

International membership growth has been sustained throughout 2025:

January 2025: 111 members (increased from 100 in October 2024)
December 2025: Increased to 120 members

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

New members in 2025 included consultants, trainees, and nurse members, representing countries across Europe, Asia, Australasia, and the Middle East. A key priority for 2026 will be implementation of a Low-Income Countries (LIC) membership pathway, enabling simplified access to the BSG membership benefits, subject to eligibility verification.

Overall, 2025 has been characterised by consolidation of strategic partnerships, expansion of educational initiatives, strengthening of grant-funded global capacity building, and steady growth in international membership engagement.

The 2025 European Specialty Examination in Gastroenterology and Hepatology (ESEGH)

The 2025 examination was conducted using proctored online delivery in the UK and around the world. The examination consisted of two sessions of three hours. During each session candidates answered 100 best-of-five questions, which were displayed in a random order. A total of 577 candidates completed both sessions, 134 of those sitting in European centres other than the UK.

For this examination 83 questions were new i.e. they had not been pre-tested or used before, and 117 items were re-used from previous diets.

The results of the 2025 examination were equated using the performance of the 2019 UK resident doctors as the base form. All future exams will be equated with the same base form until the ESEGH Board decides a change in standards.

Climate Change and Sustainability

The BSG Annual Conference

During 2025, we collaborated with our event partners, TFI Lodestar, to further embed sustainability as a core principle of BSG LIVE. This resulted in the publication of a post-conference Sustainability Report. Attendees were encouraged to travel sustainably, and international speakers were only invited if they committed to multiple roles within the programme.

We continued our relationship with Event Cycle to minimise the environmental impact of the event. Surplus materials were repurposed into positive social and environmental outcomes, including the reuse of graphics and Foamex boards. Catering was also reviewed, with exclusively vegetarian options offered on two days of the conference, and 80% of produce sourced locally.

For the first time, we introduced a dedicated Sustainability Zone at the conference. This included the commissioning of an eye-catching art installation, “Waves of Waste”, which visually interpreted the scale of endoscopic waste generated during procedures. The zone also served as the launch platform for our collaboration with the Centre for Sustainable Healthcare, including an e-learning module for staff on sustainable gastroenterology. Delegates were encouraged to make a personal commitment via the Sustainability Pledge Wall.

Finally, we received strong positive feedback on two well attended sustainability symposia.

Collaboration

We partnered with the Centre for Sustainable Healthcare (CSH) to develop training modules for staff in sustainable gastroenterology. We also worked with multiple organisations, including the UK Health Alliance

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

on Climate Change (UKHACC), to lobby for a sustainability commitment across the health and social care sector.

The Green Gastroenterology Challenge

We concluded the year by starting to plan for an exciting initiative, in collaboration with CSH called "The Green Gastroenterology Challenge" designed to empower gastroenterology professionals to lead sustainable healthcare projects. The challenge supports clinical teams to translate knowledge into action through practical, achievable change and runs as a competition for up to six clinical teams. The competition will run throughout 2026 and we hope to report back on its success in next year's report.

Our Journals

We are proud to co-own four gastroenterology journals with the BMJ, and access to these journals is a core membership benefit. In April 2024, to be more sustainable and move away from printing paper journals, the BMJ launched an e-version of both *Gut* and *Frontline Gastroenterology* in an exclusive interactive format for BSG members, which has had positive feedback. The fourth journal in the portfolio, *Gut Science*, was launched in 2025.

Gut

First published in 1960, Gut remains one of the world's leading journals covering the full breadth of gastroenterology. It publishes high-impact research and review articles, complemented by guidelines, commentaries, and educational content. The journal has an impact factor of 26.2 and is ranked 4th out of 147 journals in its Science Citation Index category.

In 2025, Professor Emad El-Omar, the Editor-in-Chief of *Gut* for the last 15 years, stepped down from this position and became Senior Advisor for the *Gut* portfolio. Three Editors-in-Chief were appointed to lead *Gut* in 2026. They are Professor Matías Ávila from University of Navarra Pamplona, Spain, Professor William Grady from Fred Hutchinson Cancer Research Centre Seattle, Washington, USA, and Professor Thomas Rösch from University Medical Center Hamburg-Eppendorf Hamburg, Germany. Professor Emad El-Omar was awarded a BSG lifetime achievement award at BSG LIVE'25.

Frontline Gastroenterology (FG)

Frontline Gastroenterology continues to publish articles that accelerate adoption of innovative and best practice, clinical quality and standards in the fields of gastroenterology, hepatology and clinical nutrition, as well as focusing on multidisciplinary research and care, patient experience, service provision and medical education. The journal achieved an impact factor of 3.3 in 2024/25 (from 2.6 in 2023/24), alongside a CiteScore of 5. The Editor-in-Chief is Dr Philip Smith who has recruited a diverse and dynamic international associate editorial board, fostered new links with BASL and the Roux Group, and has already published several special issues and increased its visibility internationally.

BMJ Open Gastroenterology (BMJOG)

Open Gastroenterology publishes quality papers across the breadth of gastroenterology, including hepatology, nutrition and endoscopy. As an open access journal, all content is free to download, read and share without restriction, ensuring the widest possible dissemination. BSG members benefit from a 30% discount on the article processing charge. BSG trainee members benefit from a 50% discount on the article processing charge. BMJ *Open Gastroenterology* has an impact factor of 2.9 and a CiteScore of 5.8. The Editor-in-Chief is Dr Christian Selinger.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Future activities – 2026

Supporting our members

- We remain committed to supporting our trainees from undergraduate study through to becoming a consultant, with education and networking opportunities at all levels. We continue to work with the SAC (Specialist Advisory Committees) and other key bodies to monitor the impact of the Shape of Training on our members.
- We will continue to offer bursaries to our members to attend BSG LIVE and other events.
- We will continue to offer bursaries to trainees to help with the costs of the Specialty exams.
- Project 90 will continue to offer exciting opportunities for all our members further in 2026.

Clinical Services and Standards

- We are expecting publication of several ground-breaking BSG documents which will have a huge impact on patient care.
- Various Quality Improvement projects are underway, including a suite of programmes to improve outcomes in Acute Upper GI Bleeding which are planned to launch in 2026.

Research

- We will support the growing engagement of Trainees and Allied Health Professionals in clinical research.
- We will drive forward our Priority Setting Partnerships and look forward to seeing these take shape.
- We are focused on rejuvenating a disenfranchised, disengaged and 'burnt out' workforce where research has fallen to the bottom of their agenda post COVID-19.

Education and Events

- We will continue to deliver high-quality education for our members.
- Planning for our next Annual Meeting, BSG LIVE'26 is well underway. Taking place in Liverpool, we will offer live streaming of content to enhance the virtual experience, as well as hands-on training EndoVillage. We also plan to develop the themes of sustainability and innovation throughout the event. We will be hosting a joint session with the Chinese Society of Gastroenterology.
- We also have several exciting events planned for 2026, including IBD 360 and a joint BAPEN/BSG event and a clinical endoscopist event in the autumn.
- We will continue our successful annual trainee events programme, with Taster, Management and Leadership, and Education courses all underway, as well as our annual 'National Introduction Day' to those trainees who are new to specialty training.
- We also have webinars planned on topics spanning endoscopy, women in gastroenterology, and collaborations with *Frontline Gastroenterology*.

International

- We remain committed to consolidating and expanding collaborations with other international organisations. The official signing of an MoU with the Indian Society of Gastroenterology will take place at BSG LIVE'26.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Our Structure and Governance

The BSG is a charitable company limited by guarantee (Company Number 08124892 (England and Wales), Charity Number 1149074). The Memorandum and Articles of Association is BSG's governing document.

The charity controls the subsidiary entity, BSG Limited (Company Number 3021266) (England and Wales).

Our Structure

Board of Trustees

The business of the Charity is managed by the Board of Trustees subject to the provisions of the Companies Act, Charities Act and the Society's Rules. The Board of Trustees consists of six independent Trustees, two elected members of Council and five Society officers. One of those officers, the BSG President chairs the Board.

No Trustee received any remuneration for services as a member of the Board. 14 Trustees were reimbursed expenses totalling £7,651 (2024 – 11 Trustees received expenses totalling £11,421). All expenses were incurred on Society business. No Trustee had any beneficial interest in any contract with the Society whilst serving on the Board.

New Trustees receive an induction pack. This includes the BSG's Memorandum and Articles, last audited annual report and financial statements, Charity Commission guidance on the responsibilities of charity Trustees, and a copy of the Good Trustee Guide, published by the National Council of Voluntary Organisations, for their reference. Trustees are also required to attend a training session on various topics relevant to Trustees' duties and responsibilities. The Trustees met twice face to face, and twice remotely in 2025.

Members of the Board of Trustees

Prof C Rees	*(President and chair of trustees 2024-2026)*
Dr H Gordon	*(President-Elect 2024-2026)*
Dr S Al-Shamma	*(Senior Secretary 2025-2027)*
Ms M Azdejkovic	*(Independent Lay Trustee)*
Prof P Bhandari	*(Vice President Endoscopy 2024-2026)*
Mr T Budd	*(Independent Lay Trustee)*
Dr M Cowan	*(Elected Councillor)*
Mr T Jones	*(Independent Lay Trustee)*
Ms S Marshall	*(Elected Councillor)*
Mr P McCauley	*(Independent Lay Trustee)*
Prof D S McPherson	*(Vice President Hepatology)*
Dr A J Morris	*(Treasurer)*
Mrs V Valentine	*(Independent Lay Trustee)*
Mrs M Watters	*(Independent Lay Trustee)*

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

The Executive Committee

The Executive is responsible for overseeing the day to day running of the Society supported by the BSG Office. All members of this committee are appointed by open competitive interview, chaired by a lay member of the Board of Trustees and hold delegated authority from the Trustees. This is the Society's operational board.

The BSG President serves two years, having previously served two years as President-Elect. The current President, Prof Colin Rees will serve until June 2026, when he will be succeeded by the current President-Elect Dr Harriet Gordon. The Vice President (Endoscopy) and the Vice President (Hepatology) currently serve for two years as Deputy and then two years as Vice President. The Secretaries of the Society serve for two years as Secretary and then two years as Senior Secretary.

The Treasurer serves for two years with the option to extend for a further year, and the Chairs of the Education, Research, Training, CSC and International Committees serve for two years as Deputy and two years as Chair.

Members of the Executive

Prof C Rees	*(President 2024-2026)*
Dr H Gordon	*(President-Elect 2024-2026)*
Dr S Al-Shamma	*(Senior Secretary 2025-2027)*
Dr R Bevan	*(Chair, Education Committee 2025-2027)*
Prof P Bhandari	*(Vice President Endoscopy 2024-2026)*
Dr K Clark	*(Chair, Training Committee 2025-2027)*
Dr O Elshaarawy	*(Chair, International Committee 2025-2027)*
Dr M Kurien	*(Chair, Clinical Services Committee 2024-2026)*
Mrs S Linnington	*(CEO 2023-)*
Prof D S McPherson	*(Vice President Hepatology 2025-2027)*
Dr A J Morris	*(Treasurer 2024-2026)*
Dr C Mountford	*(Secretary 2025-2027)*
Prof D Shawcross	*(Chair, Research Committee 2024-2026)*

The Council

The professional activities of the Society are overseen by a Council with delegated authority from the Board of Trustees. The Council has responsibility for advising the Board on all matters pertaining to professional practice and the reputation of the Society. All members of the Executive are voting members of Council.

Members of Council

Prof C Rees	*(President 2024-2026)*
Dr H Gordon	*(President-Elect 2024-2026)*
Dr S Al-Shamma	*(Senior Secretary 2025-2027)*
Dr R Bevan	*(Chair, Education Committee 2025-2027)*
Prof P Bhandari	*(Vice President Endoscopy 2024-2026)*
Dr E Bird-Lieberman	*(Guidelines Lead, Clinical Services Committee 2024-2027)*
Dr M Bose	*(QI Lead, Deputy Clinical Services Committee 2024-2026)*
Dr K Clark	*(Chair, Training Committee 2025-2027)*
Dr M Cowan	*(Elected Member 2023-2026)*
Dr L Donnelly	*(Chair, BSG Nurses Committee 2024-2027)*

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Dr O Elshaarawy	*(Chair, International Committee 2025-2027)*
Dr S Everett	*(Elected Member 2023-2026)*
Prof B H Hayee	*(Elected Member 2025-2028)*
Dr G Kerry	*(Chair, Trainee Committee 2025-2026)*
Dr M Kurien	*(Chair, Clinical Services Committee 2024-2026)*
Mrs S Linnington	*(CEO 2023-)*
Ms S Marshall	*(Elected Member 2025-2028)*
Prof D S McPherson	*(Vice President Hepatology 2025-2027)*
Dr A J Morris	*(Treasurer 2024-2026)*
Dr C Mountford	*(Secretary 2025-2027)*
Dr A Mukhopadhya	*(Elected Member 2023-2026)*
Dr B Oates	*(Elected Member 2025-2028)*
Prof M Rutter	*(Elected Member 2025-2028)*
Prof D Sanders	*(Elected Member 2025-2028)*
Dr L Scovell	*(Workforce Lead 2025-2028)*
Prof D Shawcross	*(Chair, Research Committee 2024-2026)*
Prof S Thomas-Gibson	*(Elected Member 2024-2027)*
Prof N Trudgill	*(Elected Member 2025-2028)*

Observer members

Mr H Athur	*(ACPGBI)*
Mr J Catton	*(AUGIS)*
Dr N Thompson	*(BAPEN)*
Dr I Rowe	*(BASL)*
Dr D Campbell	*(BSPGHAN)*
Dr C Selinger	*(BMJ Open Gastroenterology)*
Dr P Smith	*(Frontline Gastroenterology)*
Prof M A Ávila	*(Gut Journal)*
Dr W Grady	*(Gut Journal)*
Prof T Rösch	*(Gut Journal)*
Dr U Gill	*(Gut Science)*
Ms S Hudson	*(Guts UK)*
Dr M Sloan	*(PCSG)*
Prof K Roberts	*(PSGBI)*
Dr A Jawhari	*(SAC)*

The business of Council is informed by five higher committees and their sub-committees:

- The **Clinical Services Committee** (CSC) is responsible for compiling and disseminating good practice in gastroenterology services.
- The **Research Committee** is responsible for assisting in formulating policy on gastrointestinal research and the Society's research agenda.
- The **Training Committee** is responsible for ensuring that the curriculum for training in gastroenterology is delivered uniformly throughout the UK.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

- The **Programme and Education Committees** are responsible for the scientific and educational content of meetings held by the Society and for nominations for appropriate fellowships and awards and endorsement of external meetings.
- The **International Committee** is responsible for delivery of the international strategy of the Society which implements the BSG's charitable objects in the international setting.

The Society is represented at regional level by regional leads within the CSC. Separately there are sections for the academic and professional advancement of specialist interests. These sections are: Adolescents & Young Persons, Association of GI Physiology Professions, Colorectal, Endoscopy, Gastroduodenal, Inflammatory Bowel Disease, Liver, Neurogastroenterology & Motility, Nurses, Oesophageal, Pancreatobiliary, Pathology, Small Bowel & Nutrition, Supporting Women in Gastroenterology (SWiG) and Trainees. Section Chairs are represented on the Education (and Programme) Committee and Research Committee.

Operational Staff

The Society is administered by an office in London, staffed by 14 FTE employees. The staff support the activities of the BSG offices, committees and working groups. The Society also maintains several contracts for specialist professional services, including HR, accountancy and web development, and consultants continue to be contracted to fulfil specific needs or support projects. Remuneration for key management personnel is set by benchmarking exercises, which are carried out by external HR Consultants. Annual performance reviews are carried out by employees' line managers, or in the case of the Chief Executive, by the President. Ultimate responsibility for all staff (delegated authority from the Trustees) lies with the President.

Fundraising

The charity does not actively solicit donations and therefore is not registered with the Fundraising Regulator and does not subscribe to any fundraising codes of practice. On occasion, when donations from individuals are received, the charity aims to protect personal data and never sells data or swaps data with other organisations.

Organisational Governance Achievements

- All trustees have received training in their role.
- The BSG Strategy 2024-2026 was published in July 2024. A BSG Strategy Day is planned for October 2026.
- All Section committees have strategic plans in place. Each committee has an established light touch regulation and appraisal process, undertaken on an annual basis by the President-Elect, where they are encouraged to review their terms of reference so that they continue to meet the Society's charitable objects.
- Various project managers have been contracted to progress the strategic projects for the Society as a whole and the committee strategies.
- All the higher committees have moved to a "Deputy and Chair" organisation. All Chairs serve for four years, two years as Deputy and two years as the Chair. This gives the Chair a defined period to familiarise themselves with the workings of the committee and of the executive and provides resilience and better distribution of workload.
- Elected councillors are asked their advice on key issues at every Council meeting. They have their own e-mail box for comments from members.
- Elections have been held for Sections and Clinical Research Groups to ensure that membership of the

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

committees is renewed, and that all BSG members can participate in the work of the Society. In 2024 the election process was expanded to include International Zonal Leads.

Governance Review

An independent Governance Review was commissioned by the Board of Trustees in September 2024. The recommendations were reviewed by the Board in 2025, and the following recommendations have been implemented in 2025 with the remaining being carried out in 2026 with any changes required to Rules and Regulations to be approved by the Board.

- The position of President-Elect/President has transitioned from an appointment model to an open member election, with nominations taking place in December 2025 and Elections taking place in March/April 2026. The new President-Elect will take up office at the Annual Meeting in June 2026. This process will be overseen by a Nominations Committee made up of Lay Trustees, Officers, Elected Councillors and the CEO.
- Senior Officer Job Descriptions have been reviewed to strengthen governance by clarifying expectations, decision making responsibilities and leadership standards across the senior volunteer structure.
- The three-tier governance structure (Board-Executive-Council) has been finalised with Matters Reserved for each committee being approved at the Board meeting in December 2025.
- Elected Councillors appointed as Trustees are chosen by the Elected Councillors from their number.
- A dedicated Elected Councillor Trainee and Elected Councillor Nurse have been created for the 2026 Elections.

Equality, Diversity and Inclusion

"The British Society of Gastroenterology (BSG) believes that equity of opportunity is of fundamental importance for everyone involved in our organisation. We welcome and actively seek to recruit individuals to our activities regardless of race, religion, ethnic origin, disability, age, gender, sexual orientation or working pattern. The BSG aims to encourage diversity of membership in all committees, senior roles and staff."

The BSG not only seeks to promote equal opportunities for all our members but also actively tries to encourage members who might not immediately see themselves as potential contributors to the Society's work, to take on roles. We regard diversity as one of our greatest assets. To enable this:

- An Equality, Diversity and Inclusion (ED&I) statement is included with all job descriptions.
- Personalised advice and encouragement are available to anyone considering a position within the Society.
- Our website features role models and individual member stories, drawn from the full diversity of our membership.

ED&I is at the heart of the BSG's plans and activities. We recognise that there are inequalities in representation and opportunity within gastroenterology and are committed to addressing these both inside and, where possible, outside the organisation. A comprehensive ED&I strategy was launched in 2023, and a working group monitors the progress of this strategy via key performance indicators and timelines which are performance managed at Executive level and reported at Board level.

A new website was launched in March 2024 to improve the member experience and enable the organisation to collect more ED&I data.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Risk Management

The Trustees of the Society have overall responsibility for risk management within the Society.

Key Risks and Mitigation

A review of the Society's formal risk register is a standing item at every meeting of Board of Trustees, which implements mitigations as and when required. The Risk Register is maintained by the operational team under the leadership of the CEO. The CEO holds overall responsibility for the oversight and maintenance of the risk register.

Financial

A Finance and Investment Committee (FIC), consisting of the BSG Treasurer, three of the Society's independent Trustees, the President, President-Elect, and the Chief Executive, reviews the financial activities of the Society, including investment decisions, to mitigate the risk of loss of income and reports directly to the Board of Trustees.

Failure of Annual Meeting

The Annual Meeting is the main event in the BSG's calendar. As well as being a major source of revenue, it is key to maintaining and enhancing the reputation of the Society. The risk to the Society should the meeting be cancelled, go ahead without an optimal programme, or fail to attract sufficient delegate numbers or sponsorship, is therefore substantial but had never occurred prior to 2020.

The Society has prepared for such an event by assiduous planning. This is led by senior executive officers, and careful project management through professional conference organisers. In addition, the BSG has, as part of its free reserves, £1,000,000 designated to cover expenses in the event of a meeting failing to take place or having to be curtailed.

Potential Reduction in Publishing Revenues

The Society relies on its publishing partnership with the BMJ Publishing Group Ltd for a significant percentage of its income. However, the nature of the publishing landscape is changing and an initiative called 'Plan S' is likely to have a material impact on this revenue stream in the future. Plan S is an initiative for open-access science publishing launched in 2018 by a consortium of national research agencies and funders from 12 European countries. The plan requires scientists and researchers who benefit from state-funded research organisations and institutions to publish their work in open repositories or in journals that are available to all.

The Society has continued to work closely with BMJ publications. After discussion, it was agreed to make *Gut* and *Frontline Gastroenterology* hybrid journals, designating them as being "in transition" allowing them to continue to publish all types of material.

The future of Plan S is still not clear, and the situation is complicated by other long-term trends in publishing, such as a move away from paper to electronic copies. Some reduction in income seems probable over the coming five years but the Society is aware and taking measures to minimise the impact. Meanwhile, income from BMJ has increased in 2025 partly due to lower production costs and an increase in open access fees.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Risk Mitigation, Guidelines, and Professional Advice

The Society never gives advice to individual members of the public. All its advice is generic. The Society publishes guidelines and professional advice. There is a risk that a company or individuals might disagree with the findings and attempt to contest them.

Guidelines are developed by working groups of professionals usually including lay members of the public, using strict evidence-based criteria based on literature searches and the grading of evidence which are generally subject to external review and published in peer reviewed journals.

Financial report for the year

Results for the year

- The consolidated statement of financial activities is shown on page 36 of the annual report and financial statements.
- Income for the year was £4,518,697 (2024 - £3,891,231). The increased income in 2025 is due to the annual conference having increased delegates and sponsorship and an increase in publication income.
- The Society incurred expenditure of £4,444,582 (2024 - £3,800,620) the increased cost in 2025 relates to the direct costs of events, including the annual conference.
- The results for the year show an overall decrease in funds of £293,670 (2024 increase of £296,440). This includes unrealised losses on investments of £367,141 (2024- unrealised gains of £205,829) (see note 12). Net income before investment gains and losses for the year was a surplus of £74,115 (2024 - net surplus of £90,611).
- The profit within BSG Limited amounted to £457,772 (2024 - profit of £207,034).

Investment Policy and Performance

In May 2020, after a retender process, the FIC awarded the management of the Society's investment portfolio to CCLA. The Society's investment strategy is medium risk. The policy takes account of ethical considerations such as restrictions on tobacco and alcohol-related investment. In addition, the Trustees agreed that whilst supporting companies involved in drug development is desirable, all such investments should be held at 'arm's length' (i.e. in funds). Details of the Society's investments are set out in note 12 to the financial statements.

The Trustees consider the fund to have performed acceptably during 2025 within the context of the economic environment but reserve the right to review and tender for alternative providers as part of an active approach to investment oversight.

Reserves and Going Concern Assessment

The Trustees continue to actively address the issue of reserves in the context of future plans and requirements of the Society. The cash needs of the Society are well within the assets it holds and the income it generates.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

The objective is to maintain sufficient funds to support the key activities of the Society for one calendar year. This includes the annual meeting, 12 months' staff costs, and funds sufficient to discharge essential operating expenses, giving a total minimum required free reserve of approximately £1,600,000. The general funds, or free reserves, of the group at the year-end were £2,403,489 (2024 - £1,762,187) and this is broadly in line with the target set out above. The level of free reserves is regularly reviewed by Trustees. It is expected that at a Strategy Day planned in October 2026, plans to spend the free reserves on projects will be discussed.

Total funds of the charity at the year-end were £8,305,839 (2024 - £8,599,509). This included restricted funds of £87,993 (2024 - £100,114) and designated funds at the year-end totalled £5,814,357 (2024 - £6,737,208). Details of the designated funds are given in note 15 to the financial statements.

There is a reasonable expectation that the BSG has adequate resources to continue in operational existence for the foreseeable future. The Trustees believe that there are no material uncertainties that call into doubt the Group and the Charity's ability to continue operating as a going concern. In making this decision, the Trustees have also taken into consideration the risks and conclude that the Group and the Charity can sustain their operations for a period of at least 12 months from date of signing these financial statements. Consequently, the financial statements have therefore been prepared on the basis that the Group and the Charity remain a going concern.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Statement of Trustees' responsibilities

The Trustees (who are also directors of the BSG for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the group for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Each of the Trustees confirms that:

- so far as the Trustee is aware, there is no relevant audit information of which the charitable company's auditor is unaware; and
- the Trustee has taken all the steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

Approved by the Trustees and signed on their behalf by:

Signed by:

Professor Colin Rees

57B5108BED0B4F9...

Chair of the BSG Board of Trustees Approved by the Trustees on: 26/6/2026

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF BRITISH SOCIETY OF GASTROENTEROLOGY

Opinion

We have audited the financial statements of the BSG (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2025 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2025 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Auditor's Responsibilities for the audit of the financial statements

We have been appointed as auditor under the Companies Act 2006 and section 151 of the Charities Act 2011 and report in accordance with those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and, in respect of the consolidated financial statements, to the charity's trustees, as a body, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body, for our audit work, for this report, or for the opinion we have formed.

Signed by:
Moore Kingston Smith LLP
9ED5D7CC3357445...

Adam Fullerton (Senior Statutory Auditor)

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

6th Floor
9 Appold Street
London
EC2A 2AP

Date: 3/7/2026

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Consolidated statement of financial activities Year to 31 December 2025 (incorporating income and expenditure)

	Notes	Unrestricted £	Restricted £	2025 **Total funds £**	Unrestricted £	Restricted £	2024 **Total funds £**
Income							
Membership subscriptions	1	588,004	-	**588,004**	566,550	-	**566,550**
Investment income	2	241,199	-	**241,199**	236,353	-	**236,353**
Other		89,276	-	**89,276**	70,409	-	**70,409**
Charitable activities:	3						
Education and training		2,472,894	11,300	**2,484,194**	2,114,268	22,210	**2,136,478**
GI research		1,096,024	-	**1,096,024**	881,441	-	**881,441**
Service standards		-	20,000	**20,000**	-	-	-
Total income		4,487,397	31,300	**4,518,697**	3,869,021	22,210	**3,891,231**
Expenditure							
Cost of membership services	4	129,615	-	**129,615**	103,958	-	**103,958**
Cost of charitable activities:	5						
Education and training		3,131,566	24,292	**3,155,858**	2,604,467	16,171	**2,620,638**
GI research		744,905	-	**744,905**	631,858	3,682	**635,540**
Service standards		275,671	19,129	**294,800**	272,830	24,285	**297,115**
International		119,404	-	**119,404**	143,369	-	**143,369**
Total expenditure		4,401,161	43,421	**4,444,582**	3,756,482	44,138	**3,800,620**
Net income/(expenditure) before gains/(losses) on investments	8	86,236	(12,121)	74,115	112,539	(21,928)	**90,611**
Gains/(losses) on investments	12						
Unrealised (losses)/gains on investments		(367,141)	-	**(367,141)**	205,829	-	**205,829**
Realised (losses)/gains on investments		(644)	-	**(644)**	-	-	**-**
		(367,785)	-	**(367,785)**	205,829	-	**205,829**
Net (expenditure)/income and net movement in funds for the year		(281,549)	(12,121)	**(293,670)**	318,368	(21,928)	**296,440**
Reconciliation of funds							
Fund balances brought forward at 1 January		**8,499,395**	**100,114**	**8,599,509**	**8,181,027**	**122,042**	**8,303,069**
Fund balances carried forward at 31 December		**8,217,846**	**87,993**	**8,305,839**	**8,499,395**	**100,114**	**8,599,509**

All of the charity's activities derived from continuing operations during the above financial year.

All recognised gains or losses are included in the above statement of financial activities.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Balance Sheet 31 December 2025

	Notes	Group 2025 £	Group 2024 £	Charity 2025 £	Charity 2024 £
Fixed Assets					
Tangible Assets	11	**26,867**	38,888	**26,867**	38,888
Investments	12	**6,809,989**	7,653,549	**6,809,990**	7,653,550
		6,836,856	7,692,437	**6,836,857**	7,692,438
Current Assets					
Debtors	13	**738,289**	880,679	**1,244,890**	844,416
Cash at bank and in hand		**1,017,509**	488,775	**473,930**	332,223
		1,755,798	1,369,454	**1,718,820**	1,176,639
Liabilities					
Creditors falling due within one year	14	**(286,815)**	(462,382)	**(249,838)**	(269,568)
Net current assets		**1,468,983**	907,072	**1,468,982**	907,071
Total net assets		**8,305,839**	8,599,509	**8,305,839**	8,599,509
The funds of the charity:					
Unrestricted funds:					
General funds		**2,403,489**	1,762,187	**2,403,489**	1,762,187
Designated funds	15	**5,814,357**	6,737,208	**5,814,357**	6,737,208
Restricted funds	16	**87,993**	100,114	**87,993**	100,114
	17	**8,305,839**	8,599,509	**8,305,839**	8,599,509

The consolidated financial statements of the group incorporate the financial statements of the Society and the trading subsidiary it controls, BSG Limited. A separate statement of financial activities and income and expenditure account are not represented for the charity itself following the exemption afforded by section 408 of the Companies Act 2006. The net expenditure of the charity for the year was £293,670 (2024: net income of £296,440).

Approved by the Trustees and signed on their behalf by:

Signed by:
57B5108BED0B4F9...
Professor Colin Rees

Chair of the BSG Board of Trustees Approved

on: 26/6/2026

British Society of Gastroenterology

Registered Company Number: 08124892 (England and Wales)

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Statement of cash flows Year to 31 December 2025

	Notes	**2025 £**	2024 £
Cash flow from operating activities:			
Net cash (used in) provided by operating activities	A	**(184,213)**	(190,962)
Cash flow from investing activities:			
Dividends and interest from investments		**241,199**	236,353
Proceeds from sale of investments		**475,775**	-
Purchase of tangible fixed assets		**(4,027)**	(18,379)
Net cash provided by investing activities		**712,947**	217,974
Change in cash and cash equivalents in the year		**528,734**	27,012
Cash and cash equivalents at 1 January	B	**488,775**	461,763
Cash and cash equivalents at 31 December	B	**1,017,509**	488,775

Notes to the statement of cash flows for the year to 31 December

A Reconciliation of net movement in funds to net cash flow from operating activities

	2025 £	2024 £
Net movement in funds (as per the statement of financial activities)	**(293,670)**	296,440
Adjustments for:		
Depreciation charge	**16,499**	13,870
(Gains)/losses on investments	**367,785**	(205,829)
Dividends and interest from investments	**(241,199)**	(236,353)
Deficit on disposal of tangible fixed assets	**(451)**	-
Decrease/(Increase) in debtors	**142,390**	(76,536)
(Decrease)/Increase in creditors	**(175,567)**	17,446
Net cash (used in) provided by operating activities	**(184,213)**	(190,962)

B Analysis of changes in net debt

	1 January 2025 £	Movement in year £	**31 December 2025 £**
Cash at bank and in hand	**488,775**	528,734	**1,017,509**
Total cash and cash equivalents	**488,775**	528,734	**1,017,509**

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Principal accounting policies Year to 31 December 2025

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are laid out below.

Basis of preparation

These financial statements have been prepared for the year to 31 December 2025, with comparative information for the year to 31 December 2024, and are presented in sterling and rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant accounting policies below or the notes to these financial statements.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006 and the Charities Act 2011.

The charity constitutes a public benefit entity as defined by FRS 102.

Critical accounting estimates and areas of judgement

Preparation of the financial statements requires the Trustees and management to make significant judgements and estimates.

The items in the financial statements where these judgements and estimates have been made include:

- estimating the useful economic life of tangible fixed assets for the purposes of determining the annual depreciation charges; and
- estimating future cash flows for the purpose of determining the going concern status of the group.

Assessment of going concern

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The Trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements.

The Trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the group and the charity to continue as a going concern. They are of the opinion that the group and the charity will have sufficient resources to meet its liabilities as they fall due. The Trustees do not have material concerns regarding the group and the charity's ability to continue as a going concern.

With regard to the next accounting period, the year ending 31 December 2026, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets.

Basis of consolidation

The consolidated financial statements of the group incorporate the financial statements of the Society and the trading subsidiary it controls, BSG Limited. These have been consolidated on a line by line basis. A separate statement of financial activities and income and expenditure account are not represented for the charity itself following the exemption afforded by section 408 of the Companies Act 2006.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Income recognition:

Income is recognised in the period in which the group and the charity have entitlement to the income, the amount of income can be measured reliably, and it is probable that the income will be received.

Subscription income

Subscription income is accounted for in the financial period for which it is due.

Publication income

The Society has a contract with BMJ Publications for the publication of the journals, which gives 50% of any surplus on a quarterly basis to the Society. The Society also receives advertising income from the publications, via BSG Limited. All publication income is accounted for on a receivable basis.

Scientific meetings

The income arising from scientific meetings is recognised on a receivable basis.

Donations

Donations are credited to the statement of financial activities in the year in which they are received.

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Expenditure recognition

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the group and the charity to make a payment to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

a) Cost of membership services includes an allocation of staff time.

b) Expenditure on charitable activities comprise expenditure on the Society's primary charitable purposes as described in the Trustees' report. The costs for each activity include grants payable, other direct costs and support costs, which are apportioned on the level of activity in each area.

c) Grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant, and has satisfied all relevant conditions. Grants approved but not paid at the end of the financial year are accrued for. Grants where the beneficiary has not been informed or has to meet certain conditions before the grant is released are not accrued for but are noted as financial commitments in the notes to the financial statements.

Expenditure is stated net of VAT and irrecoverable VAT is included in support costs.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Allocation of support and governance costs

Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs directly attributable to the governance of the charity, including audit costs and the necessary legal procedures for compliance with statutory requirements.

Support costs and governance costs are allocated between activities with the allocation based on staff time use.

Pension costs

The charity operates a defined contribution scheme on behalf of its employees. The assets are held in separately administered funds. Costs are charged to the statement of financial activities in the period to which they relate.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off the cost of each asset over its estimated useful life:

- Office furniture, fittings and equipment - 5 years
- Leasehold building - 25 years

Items used in the day to day running of the Society and with a cost in excess of £500 are capitalised, and are stated at cost less accumulated depreciation.

Debtors

Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments are valued at the amount prepaid.

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short term liquid investments with original maturities of three months or less from the date of acquisition.

Creditors and provisions

Creditors and provisions are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the group and the charity anticipates it will pay to settle the debt.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Fund structure

The Society has various types of funds for which it is responsible, and which require separate disclosure. These are as follows:

General funds

Funds which are expendable at the discretion of the Trustees in furtherance of the objects of the Society.

Designated funds

Funds which are set aside as part of the Society's unrestricted funds for particular purposes in the future.

Restricted funds

Funds raised for, and their use restricted to, a specific purpose, or donations subject to donor imposed conditions.

Investments

Listed investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

The charity does not acquire put options, derivatives or other complex financial instruments.

Realised gains (or losses) on investment assets are calculated as the difference between disposal proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value at that date. Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

Financial instruments

The charity only holds basic financial instruments as defined in FRS 102. The financial assets and financial liabilities of the charity and their measurement basis are as follows:

Financial assets – other debtors are basic financial instruments and are debt instruments measured at amortised cost. Listed investments are a basic financial instrument as detailed above. Prepayments are not financial instruments.

Cash at bank – classified as a basic financial instrument and is measured at face value.

Financial liabilities – accruals and other creditors are financial instruments, and are measured at amortised cost.

Taxation

The Society is a registered charity and therefore is not liable for income tax or corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to registered charities.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

Notes to the financial statements Year to 31 December 2025

1. Subscriptions

	Unrestricted funds	
	2025	2024
	£	£
Membership subscriptions	**588,004**	566,550
Total funds	**588,004**	566,550

2. Investment income

	Unrestricted funds	
	2025	2024
	£	£
Income from listed investments	**209,795**	217,064
Interest receivable	**31,404**	19,289
Total funds	**241,199**	236,353

3. Income from charitable activities

	Unrestricted £	Restricted £	**2025 Total funds £**	Unrestricted £	Restricted £	**2024 Total funds £**
Education and training						
. Annual Conference and Campus	2,341,734	-	**2,341,734**	2,007,735	-	**2,007,735**
. Trainee events and meetings	47,117	-	**47,117**	50,083	-	**50,083**
. Other education events	60,343	9,460	**69,803**	40,800	18,000	**58,800**
. Sponsorship income	23,700	-	**23,700**	15,650	-	**15,650**
. Other income	-	1,840	**1,840**	-	4,210	**4,210**
	2,472,894	11,300	**2,484,194**	2,114,268	22,210	**2,136,478**
GI Research						
. 'GUT', Frontline Gastroenterology and Open Gastro journals	1,066,484	-	**1,066,484**	881,441	-	**881,441**
. Research CRG events and meetings	29,540	-	**29,540**	-	-	**-**
	1,096,024	-	**1,096,024**	881,441	-	**881,441**
Service Standards						
.Service Standards events	-	20,000	**20,000**	-	-	-
	-	20,000	**20,000**	-	-	-
Total funds	3,568,918	31,300	**3,600,218**	2,995,709	22,210	**3,017,919**

4. Cost of membership services

	Unrestricted funds	
	2025	2024
	£	£
Staff costs (note 9)	**129,615**	103,958
Total funds	**129,615**	103,958

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

5. Expenditure on charitable activities

	Unrestricted £	Restricted £	2025 Total funds £	Unrestricted £	Restricted £	2024 Total funds £
Education and training						
Direct costs:						
Annual Conference and Campus	1,788,705	-	**1,788,705**	1,658,858	-	**1,658,858**
Trainee events and meetings	78,773	-	**78,773**	88,346	-	**88,346**
Section and Committee events and meetings	219,852	24,292	**244,144**	143,210	16,171	**159,381**
Other conferences and events	-	-	**-**	-	-	**-**
Project 90	92,471	-	**92,471**	4,448	-	**4,448**
Mentoring	5,569	-	**5,569**	5,723	-	**5,723**
Staff costs (note 9)	245,994	-	**245,994**	206,233	-	**206,233**
Bursaries and Prizes	126,825	-	**126,825**	27,561	-	**27,561**
Support costs (note 6)	573,377	-	**573,377**	470,088	-	**470,088**
	3,131,566	24,292	**3,155,858**	2,604,467	16,171	**2,620,638**
GI Research						
Direct costs:						
'GUT' journal	245,000	-	**245,000**	245,000	-	**245,000**
Frontline Gastroenterology journal	120,000	-	**120,000**	120,000	-	**120,000**
Open Gastroenterology journal	-	-	**-**	-	-	**-**
Research events and meetings	39,180	-	**39,180**	5,017	3,682	**8,699**
Bursaries and prizes	5,575	-	**5,575**	19,975	-	**19,975**
Clinical Research Groups	48,120	-	**48,120**	7,365	-	**7,365**
Priority setting partnerships	150	-	**150**	40,360	-	**40,360**
Research projects	93,883	-	**93,883**	30,660	-	**30,660**
Staff costs (note 9)	55,373	-	**55,373**	48,185	-	**48,185**
Grant to Guts UK	8,556	-	**8,556**	4,878	-	**4,878**
Support costs (note 6)	129,068	-	**129,068**	110,418	-	**110,418**
	744,905	-	**744,905**	631,858	3,682	**635,540**
Service standards						
Direct costs:						
Guidelines	3,685	17,801	**21,486**	22,667	15,885	**38,552**
Meeting and other costs	20,703	828	**21,531**	19,211	-	**19,211**
Staff costs (note 9)	75,091	500	**75,591**	72,216	500	**72,716**
Support costs (note 6)	176,192	-	**176,192**	158,736	7,900	**166,636**
	275,671	19,129	**294,800**	272,830	24,285	**297,115**
International						
Direct costs:						
Staff costs (note 9)	29,294	-	**29,294**	34,260	-	**34,260**
Other costs	-	-	**-**	5,469	-	**5,469**
Grants and awards	21,830	-	**21,830**	25,129	-	**25,129**
Support costs (note 6)	68,280	-	**68,280**	78,511	-	**78,511**
	119,404	-	**119,404**	143,369	-	**143,369**
Total funds	4,271,546	43,421	**4,314,967**	3,652,524	44,138	**3,696,662**

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

6. Support costs

	Education and training £	GI research £	Service standards £	International £	**2025 Total £**
Premises expenses	53,319	12,002	16,384	6,349	**88,054**
Administration and office expenses	70,721	15,919	21,732	8,422	**116,794**
Website	88,043	19,819	27,055	10,485	**145,402**
Legal and professional fees	4,839	1,089	1,487	576	**7,991**
Human Resources	4,757	1,071	1,462	566	**7,856**
Consultancy	13,753	3,096	4,226	1,638	**22,713**
Accountancy and bookkeeping	22,141	4,984	6,804	2,637	**36,566**
Staff costs	199,206	44,841	61,213	23,722	**328,982**
Recruitment and training	9,519	2,143	2,925	1,134	**15,721**
Marketing	23,378	5,262	7,184	2,784	**38,608**
Bank charges and foreign currency (gain)	3,944	888	1,212	470	**6,514**
Depreciation and disposal of assets	9,718	2,187	2,986	1,157	**16,048**
Sundry expenses	3,288	740	1,010	391	**5,429**
Irrecoverable VAT	38,742	8,721	11,905	4,614	**63,982**
Governance costs (note 7)	28,009	6,306	8,607	3,335	**46,257**
2025 Total	**573,377**	**129,068**	**176,192**	**68,280**	**946,917**

	Education and training £	GI research £	Service standards £	International £	2024 Total £
Premises expenses	49,892	11,719	17,686	8,333	87,630
Administration and office expenses	73,409	17,243	26,022	12,260	128,934
Website	48,992	11,508	17,366	8,182	86,048
Legal and professional fees	12,421	2,917	4,403	2,074	21,815
Human Resources	6,758	1,587	2,395	1,129	11,869
Consultancy	29,163	6,850	10,338	4,871	51,222
Accountancy and bookkeeping	20,367	4,784	7,220	3,402	35,773
Staff costs	134,981	31,706	47,848	22,543	237,078
Recruitment and training	19,036	4,471	6,748	3,179	33,434
Marketing	17,147	4,028	6,078	2,863	30,116
Bank charges and foreign currency (gain)	2,715	638	962	454	4,769
Depreciation and disposal of assets	7,897	1,855	2,799	1,319	13,870
Sundry expenses	8,158	1,916	2,892	1363	14,329
Irrecoverable VAT	15,547	3,652	5,511	2,596	27,306
Governance costs (note 7)	23,605	5,544	8,368	3,943	41,460
2024 Total	470,088	110,418	166,636	78,511	825,653

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

7. Governance

	Unrestricted funds	
	2025	2024
	£	£
Council meetings	**15,295**	7,990
Trustees' meetings	**6,329**	9,970
Auditor's remuneration	**24,633**	23,500
Total funds	**46,257**	41,460

None of the Trustees received remuneration from the charity in respect of their services as Trustees (2024 - none).

8. Net income before gains/(losses) on investments

This is stated after charging:

	Unrestricted funds	
	2025	2024
	£	£
Staff costs (note 9)	**887,562**	753,652
Depreciation (note 11)	**16,499**	13,870
Loss on disposal of tangible fixed assets	**451**	-
Auditor's remuneration		
Audit fees – current year	**24,633**	23,500
Non-audit services	**-**	-

9. Staff costs, remuneration of key management and Trustees' remuneration

	Unrestricted funds	
	2025	2024
	£	£
Wages and salaries	**707,667**	584,030
Social security cost	**73,171**	54,234
Pension cost	**56,913**	42,309
	837,751	680,573
Consultancy costs	**49,811**	73,079
	887,562	753,652

Staff costs analysed by activities:

	Unrestricted funds	
	2025	2024
	£	£
Cost of raising funds	**129,615**	103,958
Charitable activities:		
Education and training	**245,994**	206,233
GI research	**55,373**	48,185
Service standards	**75,591**	72,716
International	**29,294**	34,260
Support costs	**351,695**	288,300
	887,562	753,652

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

The average number of employees, excluding agency and self-employed consultant staff, during the year was:

	2025 No.	2024 No.
Employees	**14.5**	12.3

The number of employees who earned £60,000 or more per annum (including taxable benefits but excluding employer pension contributions) during the period was as follows:

	2025 No	2024 No
£60,000 - £70,000	**3**	2
£90,000-£100,000	**1**	1

Pension contributions for these employees totalled £24,614 (2024 – £14,491).

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the Trustees, the Chief Executive Officer, the Chief Operating Officer (new post for 2025), the Head of Marketing & Communications, the Head of Committee Services, the Head of Digital and the Head of Projects (new post for 2025). The total remuneration (including taxable benefits and employer's pension contributions) of the key management personnel for the year was £466,858 (2024 – £328,494). No Trustee received any remuneration from the Society in their ongoing role as a Trustee. Travelling and subsistence expenses were reimbursed to fourteen Trustees amounting to a total of £7,651 (2024 - £11,421 to 11 Trustees). At the year end a balance of £nil (2024 – £nil) was owed to Trustees.

10. Net income from subsidiaries

The Society has one wholly-owned subsidiary, BSG Limited, which is incorporated in England and Wales (Company Registration Number 03021266). BSG Limited conducts scientific meetings on behalf of the Society. A summary of BSG Limited's results is shown below:

	2025 £	2024 £
Turnover	**2,432,845**	2,077,989
Cost of sales	**(1,959,385)**	(1,834,622)
Gross profit	**473,460**	243,367
Administration	**(19,461)**	(39,823)
Interest receivable	**3,773**	3,490
Net profit/(loss)	**457,772**	207,034
Gift Aid donation to BSG	**(457,772)**	(207,034)
Retained profit/(loss) for the period	**-**	-

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

11. Fixed Assets/ Tangible Fixed Assets

Group and charity	Office equipment, fixtures and fittings £
Cost	
At 1 January 2025	**80,387**
Additions	**4,027**
Disposals	**(2,759)**
At 31 December 2025	**81,655**
Depreciation	
At 1 January 2025	**41,499**
Charge for the year	**16,499**
Eliminated on disposal	**(3,210)**
At 31 December 2025	**54,788**
Net book values	
At 31 December 2025	**26,867**
At 31 December 2024	**38,888**

12. Investments

	2025 £	2024 £
Market value at 1 January	**7,653,549**	7,447,720
Additions at cost	**-**	-
Disposals at opening market value	**(475,775)**	-
Realised (losses)/gains	**(644)**	
Unrealised (losses)/gains	**(367,141)**	205,829
Market value at 31 December - **Group**	**6,809,989**	7,653,549
Investment in BSG Limited	**1**	1
Society	**6,809,990**	7,653,550

At 31 December, the Group and Society's listed investments comprised the following:

	2025 £	2024 £
Unit funds (COIF Charity Fund)	**6,809,989**	7,653,549
Historical cost of investments	**6,057,113**	6,557,113

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

The total unrealised gains as at 31 December constitutes movements on revaluation and are as follows:

	2025 £	2024 £
Unrealised gains included above:		
On investments	**752,876**	1,096,436
Total unrealised gains at 31 December	**752,876**	1,096,436
Reconciliation of movements in unrealised gains		
Unrealised gains at 1 January	**1,096,436**	890,607
In respect to disposals in the year	**23,581**	-
	1,120,017	890,607
Net gains arising on revaluation arising in the year	**(367,141)**	205,829
Total unrealised gains at 31 December	**1,096,436**	1,096,436

13. Debtors

	Group		Charity	
	2025 £	2024 £	**2025 £**	2024 £
Trade debtors	**6,350**	23,750	**6,350**	23,750
VAT	**116,265**	70,542	**13,150**	17,586
Other debtors	**-**	125	**-**	125
Amounts due from subsidiary	**-**	-	**592,368**	228,502
Loan to subsidiary	**-**	-	**150,000**	150,000
Prepayments and accrued income	**615,674**	786,262	**483,022**	424,453
	738,289	880,679	**1,244,890**	844,416

Included within the above are prepayments of £59,968 (2024: £38,360) relating to deposits paid for venue hire in 2027 and 2028 which is therefore a debtor balance falling due in over one year.

14. Creditors

	Group		Charity	
	2025 £	2024 £	**2025 £**	2024 £
Trade creditors	**155,028**	247,328	**155,028**	155,295
Accruals and deferred income	**112,214**	197,142	**76,118**	97,111
Social Security and other taxation	**18,692**	17,162	**18,692**	17,162
Other creditors	**881**	750	**-**	-
	286,815	462,382	**249,838**	269,568

Included within the above is deferred income as set out below:

	Group		Charity	
	2025 £	2024 £	**2025 £**	2024 £
Deferred income brought forward at 1 January	**44,825**	68,300	**44,825**	46,800
Additional income deferred during the year	**38,767**	44,825	**38,767**	44,825
Brought forward funds released in the year	**(44,825)**	(68,300)	**(44,825)**	(46,800)
Deferred income carried forward at 31 December	**38,767**	44,825	**38,767**	44,825

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

15. Designated funds

	At 1 January 2025 £	New designations/ transfers £	Unrealised (losses)/gains £	Utilised in year £	**At 31 December 2025 £**
Clinical projects	998,038	(278,804)	-	(233,448)	485,786
Website development	37,302	120,000	-	(32,250)	125,052
Project 90	566,544	-		(142,768)	423,776
Investments	4,000,000	-	-	-	4,000,000
Investment unrealised gains	1,096,436	23,581	(367,141)	-	752,876
Tangible fixed assets	38,888	4,027	-	(16,048)	26,867
	6,737,208	(131,196)	(367,141)	(424,514)	5,814,357

	At 1 January 2024 £	New designations/ transfers £	Unrealised gains £	Utilised in year £	At 31 December 2024 £
Clinical projects	1,100,394	56,504	-	(158,860)	998,038
Membership/website development	92,392	-	-	(55,090)	37,302
Project 90	-	579,000	-	(12,456)	566,544
Investments	4,000,000	-	-	-	4,000,000
Investment unrealised gains	890,607	-	205,829	-	1,096,436
Tangible fixed assets	34,379	18,379	-	(13,870)	38,888
	6,117,772	653,883	205,829	(240,276)	6,737,208

Clinical Projects

Amount have been designated for various clinical projects including:

- **Research:** An amount has been designated for research grants.
- **Clinical Services:** Funds have been set aside for a number of worthy projects identified by Council such as audit and guidelines including open access for guidelines.
- **Research PSP*:*** Funds have been set aside as part of the Research strategy over the next 3 years, the BSG will be co-funding the development of various PSP (Priority Setting Partnerships). All requests for funding are submitted to the Research Committee for approval.
- **International:** Funds have been set aside for international grants given to members to undertake quality improvement projects internationally.
- **Endoscopy:** Funds have been set aside for various endoscopy quality improvement projects.
- **IBD**: Funds have been set aside for an IBD Quality improvement project.
- **Trainees**: An amount has been allocated to award grants to trainees to support examination costs.

The in-year transfer for clinical projects is due to some projects not utilising all the funds budgeted. These funds will be reallocated to future projects identified at the Strategy Day in October 2026.

Membership development

This has been designated for membership development.

Investments

The Society considers the income from their investment portfolio to subsidise the general operations of the

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

charity. Holding the investment portfolio helps to mitigate the risk of cyclical reductions in other income streams. The Society has determined that a minimum of £4,000,000 should be designated as an investment fund to ensure an ongoing level of supplementary income sufficient to contribute towards the cost base of the Society can be generated in perpetuity.

Investment gains

The Society has also designated the unrealised gains from investment holdings as it is not the intention to draw down on these amounts in the short term.

Tangible and intangible assets

This fund represents the net book value of the tangible and intangible assets of the Society.

16. Restricted funds

	At 1 January 2025 £	Income £	Expenditure £	At 31 December 2025 £
Endoscopy - Paul Brown travel fund	3,540	-	-	3,540
Presidents travel fund	828	-	(828)	-
Pathologists Group fund	677	-	(677)	-
Barretts Oesophagus Registry	76,255	-	(2,018)	74,237
KSS Lewisham	5,309	20,000	(18,301)	7,008
Section funds				
. Clinical Measurement	13,166	11,300	(21,258)	3,208
. NGM	339	-	(339)	-
	100,114	31,300	(43,421)	87,993

	At 1 January 2024 £	Income £	Expenditure £	At 31 December 2024 £
Endoscopy - Paul Brown travel fund	3,540	-	-	3,540
Presidents travel fund	828	-	-	828
Pathologists Group fund	2,603	-	(1,926)	677
Barretts Oesophagus Registry	79,990	-	(3,735)	76,255
KSS Lewisham	11,594	18,000	(24,285)	5,309
Section funds				
. IBD Section	1,300	-	(1,300)	-
. Clinical Measurement	15,585	4,210	(6,629)	13,166
. NGM	2,920	-	(2,581)	339
Other	3,682	-	(3,682)	-
	122,042	22,210	(44,138)	100,114

Restricted funds are as follows:

The **Paul Brown travel fund** represents a donation received from Keymed for small travel grants to UK doctors to visit Endoscopy Centres abroad to enable them to learn specific techniques.

The **Presidents travel fund** represents donations received to be utilised on travel expenses for the BSG president.

The **Pathologists Group fund** is a donation to support the annual Basil Morson Lecture.

The **Barretts Oesophagus Registry** is a donation from the Barretts Oesophagus Registry to fund Trainees to attend DDW.

Docusign Envelope ID: 1A97DD9D-5B88-83A8-8014-E2F0E404C5EC

The **Section funds** represent the income and expenditure in relation to the activities of these sections of the Society.

17. Analysis of net assets between funds

	Unrestricted funds			
	General fund £	Designated funds £	Restricted funds £	**Total funds £**
Fund balances at 31 December 2025 are represented by:				
Tangible fixed assets	-	26,867	-	**26,867**
Investments	2,057,113	4,752,876		**6,809,989**
Current assets	588,207	1,073,189	94,402	**1,755,798**
Current liabilities	(241,831)	(38,575)	(6,409)	**(286,815)**
	2,403,489	5,814,357	87,993	**8,305,839**

	Unrestricted funds			
	General fund £	Designated funds £	Restricted funds £	**Total funds £**
Fund balances at 31 December 2024 are represented by:				
Tangible fixed assets	-	38,888	-	**38,888**
Investments	2,557,113	5,096,436	-	**7,653,549**
Current assets	(374,906)	1,628,246	116,114	**1,369,454**
Current liabilities	(420,020)	(26,362)	(16,000)	**(462,382)**
	1,762,187	6,737,208	100,114	**8,599,509**

18. Ultimate control and related party transactions

The charity has no ultimate controlling party.

No Trustee received remuneration from the group and charity in respect of their services as Trustee.

19. Guts UK Charity

The Society works closely with Guts UK Charity (previously known as Core – The Digestive Disorders Foundation) (Charity Registration No 1137029 and Company Registration No 07274105 (England and Wales)) to support Guts UK's mission to support research training for young doctors and scientists, the application of new knowledge to practice and the provision of patient information to the public; Guts UK is the only charity dedicated to the whole of gastrointestinal diseases. The Chairman of the Research Committee of the BSG is a Trustee of Guts UK. The President of Guts UK is an ex-officio member of the BSG Council.

Transactions between the two charities during the year were as follows: The Society gave one grant of £8,556 to Guts UK during the year (2024 – one grant of £4,878).

20. Financial commitments

The total amount of financial commitments not included in the balance sheet is £736,397 (2024: £874,594). In order to secure bookings for future Annual Conferences the subsidiary company BSG Limited has entered into venue hire contracts for 2025 through to 2028. Under these contracts the company is committed to paying venue hire costs of £349,049 within the next 12 months and £387,348 in 2 to 5 years.